Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Chronic Lymphocytic Leukemia
78%
Chimeric Antigen Receptor T Cells (CAR-T)
72%
Lymphoma Patients
70%
Positron Emission Tomography-computed Tomography (PET-CT)
67%
Acetylcholinesterase
65%
Relapsed or Refractory
59%
Overall Survival
57%
Lymphoma
52%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
45%
Rituximab
44%
Elderly Patients
42%
Single Center
41%
Clinical Significance
40%
BNT162b2 Vaccine
40%
Progression-free Survival
38%
Retrospective multicenter Study
37%
Lymphoproliferative Disorders
37%
Non-Hodgkin Lymphoma
36%
Chimeric Antigen Receptor T-cell Therapy
35%
BNT162b2
34%
Hematological Malignancies
34%
Refractory Diffuse Large B-cell Lymphoma
33%
Response Rate
31%
COVID-19 Vaccine
28%
Hodgkin
28%
Oncology Patients
28%
Complete Response
27%
Overall Response Rate
26%
Hodgkin Lymphoma
25%
Israeli
24%
Extranodal
24%
Chronic Lymphocytic Leukemia Cells
24%
Working Diagnosis
23%
CD19
23%
COVID-19
23%
18F-FDG PET-CT
22%
Median Progression-free Survival
22%
Hodgkin Disease
22%
Disease Progression
21%
Lactate Dehydrogenase
21%
Follicular Lymphoma
21%
Anti-CD19 chimeric Antigen Receptor T Cells
20%
Partial Response
20%
Median Overall Survival
20%
Messenger RNA (mRNA)
19%
Bendamustine
19%
CT Pattern
18%
B-cell Receptor Signaling
18%
High-dose Methotrexate (HD-MTX)
18%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
93%
Overall Survival
60%
Disease
55%
Positron Emission Tomography-Computed Tomography
43%
Acetylcholinesterase
40%
Progression Free Survival
39%
Lymphoproliferative Disease
39%
Chimeric Antigen Receptor T-Cell
38%
B-Cell Chronic Lymphocytic Leukemia
37%
Non-Hodgkin Lymphoma
35%
Hematologic Malignancy
31%
Chimeric Antigen Receptor T-Cell Immunotherapy
31%
B Cell
30%
Hodgkin's Lymphoma
28%
Acetylcholinesterase
28%
Rituximab
27%
Elderly Patient
26%
Positron Emission Tomography
25%
Carboxy Terminal Sequence
23%
COVID-19
22%
Fluorodeoxyglucose F 18
21%
Hematopoietic Stem Cell
21%
Humoral Immunity
21%
Follicular Lymphoma
20%
Cell Transplantation
20%
Clinical Significance
20%
Diagnosis
19%
Cohort Analysis
19%
Adverse Event
18%
Methotrexate
18%
MALT Lymphoma
18%
B-Cell Lymphoma
18%
Tomography
16%
Morphology
15%
Survival Rate
15%
Oncology
14%
Drug Megadose
14%
Multiple Myeloma
13%
Infection
13%
Leukemia Cell
13%
Biopsy
12%
Transplantation
12%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Malignant Neoplasm
11%
Myelodysplastic Syndrome
11%
Computer Assisted Tomography
11%
Lymphadenopathy
11%
Blood Disorder
11%
CD20
10%
Gene Expression
10%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
81%
Chronic Lymphatic Leukemia
74%
Overall Survival
71%
Diffuse Large B Cell Lymphoma
69%
Nonhodgkin Lymphoma
60%
Chimeric Antigen Receptor
53%
Progression Free Survival
50%
Hodgkin Disease
43%
Rituximab
41%
Infection
38%
Acetylcholinesterase
31%
Fluorodeoxyglucose F 18
28%
COVID-19 Vaccine
28%
Lymphoproliferative Disease
28%
Lactate Dehydrogenase
25%
Adverse Event
23%
Fluorodeoxyglucose
22%
B Cell Lymphoma
22%
B Lymphocyte Receptor
20%
Fluorine 18
20%
Ibrutinib
19%
Bendamustine
19%
Mouse
18%
Chemotherapy
18%
Disease Course
15%
Neoplasm
15%
Disease Exacerbation
14%
Obinutuzumab
14%
Survival Rate
12%
Symptom
12%
Cyclophosphamide
11%
Cholinergic Receptor Stimulating Agent
10%
Hydrocortisone
10%
Anticarcinogen
10%
Prospective Study
10%
Second Cancer
9%
Neutropenia
9%
Marginal Zone Lymphoma
9%
Clinical Trial Results
9%
Endotoxin
9%
Side Effect
9%
Creatine Kinase
9%
Immunogenicity
9%
Protein Kinase C
9%
Romidepsin
9%
Antivirus Agent
9%
Carmustine
9%
Diseases
9%
Brain Tumor
9%
Receptor Agonist
9%
